What a focal cartilage defect is — and how it differs from arthritis

Being told you have a cartilage defect can sound alarming — but understanding exactly what that means is the first step towards knowing what your options are.

The inner surfaces of your knee are lined with hyaline cartilage: a smooth, pearlescent tissue that distributes load across the joint and allows bones to glide against one another with very little friction. A focal chondral defect is a localised area where this lining has worn away or been damaged — think of a pothole in an otherwise intact road surface. This is fundamentally different from osteoarthritis, in which cartilage thinning spreads across the whole joint in a diffuse, progressive pattern. With a focal defect, the surrounding cartilage is typically still intact.

When the damage extends through the cartilage and into the underlying bone, the injury is termed osteochondral rather than purely chondral. The distinction matters clinically because bone has a blood supply and some limited capacity for repair that cartilage alone does not.

The most common sites are the medial femoral condyle (the inner rounded end of the thigh bone) and the patellofemoral joint (behind the kneecap). Causes range from a single acute event — a twisting injury or direct blow — to cumulative overload over months or years. The mechanism of injury can influence how the defect behaves over time.

Symptoms vary considerably. Aching, swelling, a catching or locking sensation, and pain on activity are typical, but defect size and symptom severity do not map neatly onto one another — some substantial defects cause surprisingly little pain, whilst smaller lesions can be highly disruptive. An MRI scan can identify and characterise a defect, but imaging is one piece of clinical information, not a decision in itself. Whether the defect is the source of a patient's symptoms — and what, if anything, to do about it — requires a fuller clinical assessment.

The question most patients then ask is the obvious one: can the body repair this on its own?

Why cartilage cannot grow back on its own

The short answer is no — not to anything approaching the original tissue.

Hyaline cartilage sits beyond the reach of the body's usual repair machinery for three structural reasons. It has no blood vessels, so there is no repair signal delivered to the damaged site and no route for healing cells to arrive. It has no nerve fibres, which is why damage can be extensive before it becomes consistently painful. And it has no lymphatic drainage, removing a third pathway that would ordinarily mobilise the immune and tissue-repair response. The chondrocytes embedded within the cartilage matrix — the cells that might theoretically rebuild it — are locked inside a dense scaffold that severely limits their ability to divide or migrate towards a defect.

When the body does manage any repair at all, it fills the gap with fibrocartilage: a scar-tissue substitute estimated at roughly 70–80% of the mechanical strength of native hyaline cartilage, which wears down faster under the repetitive loading a knee endures. The Hospital for Special Surgery notes that the capacity to produce true hyaline cartilage is confined to fetal development; adult tissue cannot replicate it from scratch.

This is not, however, a counsel of despair. The biological ceiling is fixed, but the rate at which a defect deteriorates is not — and that is precisely where non-surgical management has a meaningful role.

Does an untreated defect inevitably lead to arthritis?

The evidence offers some reassurance. A 2018 systematic review by Houck and colleagues — pooling eight studies and 1,425 knees — found that patients with untreated focal chondral defects are more likely to show measurable cartilage deterioration on MRI at follow-up: increased water content, proteoglycan loss, and enlargement of the damaged area. Every study in the review that assessed progression reported it.

But that finding deserves its full context. MRI progression did not consistently translate into radiographically evident osteoarthritis, measured by Kellgren-Lawrence grading, within the study follow-up periods. Structural change on imaging and the development of established arthritis are not the same outcome — and conflating them overstates the risk most patients actually face.

Lesion size shapes that risk. Defects exceeding approximately 1 cm appear more likely to worsen over time and carry a higher potential for downstream joint damage; smaller lesions do not carry the same probability of progression.

Ding and colleagues, writing in JAMA in 2006, added a further dimension: natural history is not biologically fixed. Mechanical load, body weight, and systemic factors all influence how a defect changes — which means that modifiable factors shape the defect's trajectory, not just its starting point.

One limitation should be stated plainly: the evidence base is predominantly level 3. No long-term RCTs exist comparing watchful waiting against early intervention specifically for isolated focal chondral defects, and the optimal point at which to escalate care remains genuinely uncertain. That uncertainty is not a reason to dismiss conservative management — it is a reason to approach the decision with a specialist who can weigh an individual patient's defect characteristics, symptoms, and risk profile together.

What conservative management actually does — and where it stops

Protecting what remains — rather than recovering what is lost — is the honest framing for any non-surgical programme. The goal is symptom control and slowed structural progression; it is not tissue regeneration.

Weight and load management

Weight loss carries the strongest direct evidence for cartilage benefit: research links it specifically to slower deterioration in the medial compartment, not merely improved pain scores. Every kilogram shed reduces cumulative force across the joint with each step — which matters considerably when a focal defect is already reducing the surface area available to distribute load. High-impact activities that compress a defect directly should be modified rather than simply paused, replaced with loading patterns the remaining tissue can tolerate.

Supervised physiotherapy

A 2020 RCT by Deyle and colleagues published in the NEJM found supervised physiotherapy to be as effective as glucocorticoid injection for symptomatic knee conditions. The mechanism — load redistribution through neuromuscular optimisation and strengthening of the muscles that stabilise the joint — applies equally when the aim is to divert force away from a focal chondral defect rather than manage diffuse arthritic change. The cartilage itself is not repaired; the joint environment around it is made more forgiving.

Supplements

Glucosamine, chondroitin, and turmeric feature heavily in patient self-management. Rigorous trials have not demonstrated cartilage regrowth from any of these agents; they may modestly reduce inflammation or improve symptom scores in some patients, but neither effect constitutes structural repair and neither should be mistaken for one.

Intra-articular injections

Corticosteroid and hyaluronic acid injections are symptom managers. On current evidence, no FDA-approved injection has been shown to significantly regenerate damaged articular cartilage. Both agents have a legitimate place in the toolkit for improving comfort and function — but that role is distinct from disease modification, and conflating the two leads patients to overestimate what an injection can achieve.

When to see a specialist — and what that assessment involves

Six to twelve weeks of structured conservative care — physiotherapy, load modification, and weight management — is a reasonable first trial for most focal chondral defects. If symptoms persist beyond that window despite genuine adherence, seeing a specialist is the sensible next step, not a last resort.

Other signs that warrant earlier referral include episodes of the knee locking or giving way, a joint effusion that keeps returning after being aspirated or settling on its own, and any acute-onset defect in a younger, active patient where a larger lesion is suspected. Waiting longer in these situations does not improve the options available later.

What a specialist assessment involves

The consultation begins with a detailed history: how and when the problem started, what makes it better or worse, and how it affects daily function and activity. Clinical examination follows — assessing range of motion, joint-line tenderness, stability, and whether concurrent pathology such as a meniscus problem or malalignment is contributing.

MRI is the imaging standard for characterising cartilage defects, but the scan is one input, not a verdict. A specialist reads MRI findings alongside the clinical picture: defect size, depth, exact location (weight-bearing versus non-weight-bearing zone), and whether bone is involved all influence which pathway is appropriate. A large MRI defect in a patient with minimal functional limitation is staged and managed quite differently from a smaller defect that is stopping someone from working or playing sport.

The purpose of this assessment is classification and staging — not a commitment to surgery. It establishes whether continuing and refining conservative care is the right course, whether biologic support such as an injection is warranted, or whether a surgical conversation needs to begin. Many patients leave a first specialist appointment with a clearer conservative plan, not a date in theatre.

When surgery becomes the right conversation

Surgery enters the conversation not as a default, but as a conclusion reached through proper staging. The PRRR framework — Preserve, Repair, Regenerate, Replace — structures that process, moving from least to most invasive in response to what examination, imaging, and conservative trial have revealed.

Defect size is the clearest decision variable. Focal lesions under 2–4 cm² may be amenable to microfracture or mosaicplasty. For defects of 3 cm² or larger, the SUMMIT trial established that MACI produced superior KOOS pain and function scores versus microfracture at both two and five years — a finding that has shifted specialist practice for larger repairs.

Many patients fall between these clean categories: too much wear for a straightforward focal procedure, not yet at the threshold that makes joint replacement appropriate. Specialist staging clarifies which bucket applies — and whether a biologic option warrants a further trial first. Early RCT data on autologous adipose-derived stem cells show measurable MRI cartilage volume changes at six months, but this work remains preliminary and is not yet standard of care.

The question the article title poses does not resolve to a single answer. Small, stable lesions managed with load modification and supervised physiotherapy may remain controlled for years without any intervention. Larger or progressing defects — particularly in active patients — are more likely to reach a point where further delay narrows, rather than preserves, the surgical options. Defect size, lesion site, symptom trajectory, and patient age together determine which path applies; that determination requires proper specialist assessment, not watchful inaction.

For patients seeking that assessment in London, a consultation can be arranged via londoncartilage.com.

1. [1] Cartilage Regeneration Potential in Early Osteoarthritis: ADSC Therapy vs Hyaluronic Acid (RCT). (2025). https://doi.org/10.3390/ijms26178476 https://doi.org/10.3390/ijms26178476
2. [2] Recent Innovations in Cartilage Regeneration for Primary Knee OA: Intra-articular Injections (Review). (2023). https://doi.org/10.1177/23259671231155950 https://doi.org/10.1177/23259671231155950